第711期 | 全球医疗保健行业-免疫球蛋白：8%长期生长有保证

第711期

本篇报告导读

A key debate that has contributed to the underperformance of CSL, Grifols and Takeda, the global plasma fractionators, has been the impact of a potential new class of drugs (FcRn) on sales of immunoglobulin (Ig) in the second-biggest disease where Ig is used, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). 

CIDP is a rare condition with up to 40ktreated patients, but which accounts for some US$3bn out of US$12.8bn of global Ig sales.Leveraging the expertise of our global team, and based on a proprietary survey of 50 US neurologists, in this Global Connections Series report we review this debate and conclude that the market maybe too pessimistic on the plasma companies.

关于我们

全行业报告圈是一家专注于分享国内外各类行业研究报告/专题热点行业报告/白皮书/蓝皮书/年度报告等各类优质研究报告分享平台。所有报告来源于国内外数百家机构，包含零售消费、金融领域、互联网+、机械制造、新能源产业等专题研究.....目前已累积收集近40000+份行业报告，涉及11大板块，305个细分领域

免责声明

本平台只做内容的收集及分享，报告版权归原撰写发布机构所有，由全行业报告圈社群朋友通过公开合法渠道获得，如涉及侵权，请联系我们删除；如对报告内容存疑，请与撰写、发布机构联系